Marksans Pharma Ltd. has announced that its wholly-owned subsidiary, Relonchem Ltd., has received Marketing Authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets.

Baclofen is commonly prescribed for muscle spasms associated with multiple sclerosis, spinal cord injuries, and neurological disorders. This approval enhances Marksans Pharma’s presence in the UK pharmaceutical market, reinforcing its commitment to delivering high-quality, affordable medicines worldwide.

Marksans Pharma, headquartered in Mumbai, is engaged in research, manufacturing and marketing of generic pharmaceutical formulation in the global markets.

The company's manufacturing facilities located in India, the USA and the UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.

The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.